Dr Meredith McKean speaks to ecancer about a talk she presented at ASCO 2024 on 'PD-1–refractory advanced melanoma: how do we get to the finish line?'

She begins by explaining that a 30% response rate is really the 'bar' for the refractory melanoma setting.

Dr McKean then details three signal seeking studies in this area which showed exciting signals but perhaps didn't improve on this marker of response - while also adding extra regimens and toxicity.